Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
CNBC
Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients.
Lilly and its chief rival, Novo Nordisk, have moved to slash the cash prices of their popular obesity injections for those who want to pay entirely out-of-pocket. But employer coverage of obesity drugs remains uneven due to high costs, leaving roughly half of people with commercial insurance unable to start or stay on treatment, Lilly said in a release. List prices for Lilly's weight loss and diabetes treatments, Zepbound and Mounjaro, top $1,000 per month.
Nearly one-fifth of firms with over 200 workers, including 43% with 5,000 or more workers, said they cover GLP-1 drugs for weight loss as of October, according to a survey by the Peterson-KFF Health System Tracker.
Home sales made a small gain to start the year, but higher mortgage rates now could throw cold water on the spring season.
The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism symptoms.
Lego on Tuesday reported a 12% jump in revenue for fiscal year 2025 and reported consumer sales that far outpace the broader toy industry.
Live Nation, which owns Ticketmaster, reached a settlement with the Department of Justice over antitrust concerns.
A growing number of consumers are seeking out third spaces and membership clubs surrounding wellness, to improve their health while also socializing.
Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research.
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
A closely watched barometer for used vehicle pricing jumped last month as dealers sped to increase inventories amid optimism of a robust spring selling season.
Gap has been on a steady upswing of growth but saw worse than expected results during its holiday quarter after historic winter storms led to store closures.
Frustrated sellers who pulled homes off the market last fall are now re-listing them at a quick pace, thanks to lower mortgage rates, but supply is still low.
Travelers who are far from falling missiles, drone attacks and other geopolitical flashpoints aren't immune to ripple effects.
Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.
Target's merchandising leaders previewed the company's ambitious plans to overhaul key categories, including home and apparel, at an investor meeting.